May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired privately-held Limbus AI, a leading global provider of automated contouring software for radiation therapy. This acquisition signifies Radformation’s commitment to driving innovation and expanding its AI-driven capabilities in cancer care.
“Our mission has always been to improve the radiation therapy process, focusing on efficiency, quality, and safety in patient care,” said Kurt Sysock, CEO of Radformation. “With Limbus' innovative technology and expertise now part of our team, we are even more equipped to advance the frontier of innovative software solutions in radiation therapy.”
This merger aims to harness the collective strengths of both companies' platforms by integrating the superior features of each system, offering the most advanced AI-driven contouring solution available today. Beyond improving contouring, this effort is expected to spark further innovation, leading to new developments and improvements in radiation therapy.
“We share a similar vision to bring innovative software to patient care,” said Karl Otto, CEO of Limbus AI. “Both companies have very talented and hard working teams that, when combined, will be able to achieve great things together.”
Radformation’s acquisition of Limbus AI unites two leaders in clinical treatment planning, combining Radformation’s extensive global presence and robust product utilization – spanning 8 products used in over 1,600 clinics in 28 countries – with Limbus’ significant impact on 500,000 patients across 400 centers worldwide. This alliance will accelerate innovation, expand reach, and enhance patient outcomes worldwide, marking a new era in healthcare technology.
For more information: www.radformation.com
September 15, 2026 
